Aurobindo Pharma slips 4% post Q2 nos; Credit Suisse, Citi remain bullish

The company reported a 21.7 per cent decline in net profit at Rs 6.11 billion for the quarter ended September 2018, owing to rise in costs.

from Latest News https://ift.tt/2QDZkQ7
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd

• Tweet
• Share
• Share
• Share
• Share